buyWeak cluster of 2
Goldman Sachs Group Inc bought $2,110 of STER
owner at Sterling Check Corp.. 157 shares at an average of $13.44, traded Dec 22, 2023, filed Dec 26, 2023.
Conviction score
10Value
$2,110
157 shares
Holdings after
49,808,542
+0% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +12Role10% owner
- 0Trade size$2k at market
- -5Relative to holdingsUnder 1% of holdings (0.0%)
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (2 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000886982-23-000015, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 13, 2023 | SOpen-market sale Common Stockindirect: See footnotes | -157 | $13.58 | $2,132 | 49,808,484 | Dec 26, 2023 |
| Dec 22, 2023 | POpen-market purchase Common Stockindirect: See footnotes | +157 | $13.44 | $2,110 | 49,808,542 | Dec 26, 2023 |
Related signals
Other insiders at Sterling Check Corp. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 42Moderate | STERsell Sterling Check Corp. | Melanie Laird owner | $24M 1,414,000 shares | -13% | |
| 20Weak | Sterling Check Corp. | Goldman Sachs Group Inc owner | $2,132 157 shares | -0% | |
| 18Weak | Sterling Check Corp. | Adrian M Jones director | $2,110 157 shares | +0% | |
| 23Weak | Sterling Check Corp. | Adrian M Jones director | $2,132 157 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.